SCHEMBL25899570

SCHEMBL25899570

CN1Cc2cn(C)nc2-c2cccc(NC(=O)OC(C)(C)C)c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
IDO1 P14902 2/20 0.37
BRD4 O60885 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
P2RX7 Q99572 1/20 0.36
DRD4 P21917 1/20 0.36
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
DRD2 P14416 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
METAP1 P53582 1/20 0.34
POLB P06746 1/20 0.34
CNR2 P34972 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
GPR139 Q6DWJ6 1/20 0.34
TYK2 P29597 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766580 1.00 BRD9 (0.37) BRD9IRAK4IDO1BRD4HSP90AA1
SCHEMBL29766576 0.94 TYK2 (0.37) BRD9IRAK4IDO1BRD4HSP90AA1
SCHEMBL29766648 0.85 IDO1 (0.35) BRD9IRAK4IDO1HSP90AA1HSP90AB1
SCHEMBL25900011 0.85 IDO1 (0.35) BRD9IRAK4IDO1HSP90AA1HSP90AB1
SCHEMBL25317511 0.84 DRD4 (0.40) IRAK4DRD4POLBTYK2
SCHEMBL25901668 0.82 IDO1 (0.34) BRD9IDO1HSP90AA1HSP90AB1P2RX7
SCHEMBL29766583 0.82 IDO1 (0.34) BRD9IDO1HSP90AA1HSP90AB1P2RX7
SCHEMBL30549463 0.82 ALDH1A1 (0.44)
SCHEMBL29865987 0.81 IDO1 (0.40) BRD9IDO1GSK3BDYRK1ADRD2
SCHEMBL29842864 0.80 BRD9 (0.39) BRD9IRAK4IDO1BRD4HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055121-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LTD (GB) 2026-02-26 US disclosed
US-20250011335-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2025-01-09 US disclosed
US-12122785-B2 Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors SUDO BIOSCIENCES LIMITED (GB) 2024-10-22 US disclosed
WO-2024042361-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2024-02-29 WO disclosed
CN-117377669-A TYK2 inhibitor and application thereof 苏多生物科学有限公司 2024-01-09 CN disclosed
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2023-08-03 US disclosed
US-11613548-B2 Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors SUDO BIOSCIENCES LIMITED (GB) 2023-03-28 US disclosed
US-20220281885-A1 TYK2 INHIBITORS AND USES THEREOF JUBILANT BIOSYS LIMITED (IN) 2022-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12122785-B2 Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors TYK2, JAK1, PDXK BRD9 833/4885IRAK4 60/4885IDO1 193/4885
US-20250011335-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS TYK2, PDXK, JAK1 BRD9 543/4885IRAK4 51/4885IDO1 211/4885
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS TYK2, PDXK, JAK1 BRD9 543/4885IRAK4 51/4885IDO1 211/4885
US-20220281885-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 BRD9 430/4885IRAK4 31/4885IDO1 670/4885
US-11613548-B2 Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors TYK2, TPX2, PDXK BRD9 1187/4885IRAK4 56/4885IDO1 311/4885
US-20260055121-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, CSNK2A3, CSNK2B BRD9 708/4885IRAK4 66/4885IDO1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.